Cultivated meat company Meatable has acquired Uncommon Bio’s cultivated meat platform, including key technology, intellectual property assets, cell line and staff.
Meatable said the acquisition would “propel” it into an “unmatched position in the field”.
The addition of Uncommon Bio’s technology will reportedly accelerate product development for chicken, lamb and high-flavour breeds, while Meatable stated that its non-GMO status and regulatory-ready dossier would support faster regulatory approval in multiple regions.
Meatable went on to say that the acquisition would strengthen its intellectual property portfolio with additional patents and proprietary assets.
Jeff Tripician, CEO of Meatable, commented: “This acquisition is more than a strategic step - it sets a new standard for cultivated meat production. By combining two highly complementary platforms, Meatable is now equipped to reliably deliver high-quality cultivated meat at a global scale.
“This enables us to support the meat industry with a stable, secure, and future-proof supply of species like pork, beef, lamb, and poultry, ensuring business continuity and resilience in the face of increasingly uncertain times.”
Benjamina Bollag, CEO of Uncommon Bio, stated: “I’m incredibly proud of what we’ve built at Uncommon Bio, a legacy of innovation and bold thinking in cultivated meat. After deciding to focus on therapeutics, we wanted to find the best home for our technology and it’s exciting to see Meatable carry our work forward and apply it at scale. I look forward to continuing our collaboration and watch their continued success and global impact in the years ahead.”
Aris de Rijke, CTO at Meatable, said: “The value of the IP is strengthened by the calibre of investors who have supported Uncommon’s mission from the start.
“We’re proud to carry forward technology that has earned the trust of such respected backers, like Apollo Projects and Lower Carbon Capital, further fuelling our path toward success at scale.”
